[1] Rose PG,Bundy BN,Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 1999,340:1144-1153. [2] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004,351:1731-1740. [3] Mell LK,Schomas DA,Salama JK,et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys, 2008,70:1431-1437. [4] Cummings BJ. Current management of anal canal cancer. Semin Oncol, 2005,32:S123-128. [5] Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001,345:725-730. [6] Kim S,Lim DH,Lee J,et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys, 2005,63:1279-1285. [7] Abu-Rustum NR,Lee S,Correa A,et al. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer. Gynecol Oncol, 2001,81:88-91. [8] Green JA,Kirwan JM,Tierney JF,et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet, 2001,358:781-786. [9] Torres MA,Jhingran A,Thames HD,Jr.,et al. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys, 2008,70:118-125. [10] Brixey CJ,Roeske JC,Lujan AE,et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys, 2002,54:1388-1396. [11] Mundt AJ,Lujan AE,Rotmensch J,et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys, 2002,52:1330-1337. [12] Mell LK,Kochanski JD,Roeske JC,et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys, 2006,66:1356-1365. [13] Lhomme C,Fumoleau P,Fargeot P,et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase Ⅱ trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol, 1999,17:3136-3142. [14] Curtin JP,Blessing JA,Webster KD,et al. Paclitaxel,an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol, 2001,19:1275-1278. [15] Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol, 1961,5:255-258. [16] Roeske JC,Lujan A,Reba RC,et al. Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies. Radiother Oncol, 2005,77:11-17. [17] John C. Roeske AJM. Incorporation of magnetic resonance imaging into intensity modulated whole-pelvic radiation therapy treatment planning to reduce the volume of pelvic bone marrow irradiated. International Congress Series, 2004,1268:307-312. [18] Rose BS,Liang Y,Lau SK,et al. Correlation between radiation dose to(1)(8)F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2012,83:1185-1191. [19] Hayman JA,Callahan JW,Herschtal A,et al. Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys, 2011,79:847-852. [20] Mauch P,Constine L,Greenberger J,et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys, 1995,31:1319-1339. [21] Fajardo LF BM,Anderson RE.Hematopoietic tissue//Fajardo LF,Berthrong M,Anderson RE. Radiation pathology. Oxford: Oxford University Press,2011:379-388. [22] Mitchell MJ,Logan PM. Radiation-induced changes in bone. Radiographics, 1998,18:1125-1136,1242-1123. [23] Sacks EL,Goris ML,Glatstein E,et al. Bone marrow regeneration following large field radiation: influence of volume,age,dose,and time. Cancer, 1978,42:1057-1065. [24] Scarantino CW,Rubin P,Constine LS Ⅲ. The paradoxes in patterns and mechanism of bone marrow regeneration after irradiation, 1. Different volumes and doses. Radiother Oncol, 1984,2:215-225. [25] Lujan AE,Mundt AJ,Yamada SD,et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys, 2003,57:516-521. [26] 毛睿,齐洪志,尚革,等. Ⅱ/Ⅲ期直肠癌术后盆腔调强放疗计划方法的剂量学比较研究. 中华放射肿瘤学杂志, 2011,20:411-413. [27] Sherley JL,Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem, 1988,263:8350-8358. [28] Everitt S,Hicks RJ,Ball D,et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2009,75:1098-1104. [29] Blomlie V,Rofstad EK,Skjonsberg A,et al. Female pelvic bone marrow: serial MR imaging before,during,and after radiation therapy. Radiology, 1995,194:537-543. [30] Sugimura H,Kisanuki A,Tamura S,et al. Magnetic resonance imaging of bone marrow changes after irradiation. Invest Radiol, 1994,29:35-41. [31] Stevens SK,Moore SG,Kaplan ID. Early and late bone-marrow changes after irradiation: MR evaluation. Am J Roentgenol, 1990,154:745-750. [32] Yankelevitz DF,Henschke CI,Knapp PH,et al. Effect of radiation therapy on thoracic and lumbar bone marrow: evaluation with MR imaging. AJR Am J Roentgenol, 1991,157:87-92. [33] Otake S,Mayr NA,Ueda T,et al. Radiation-induced changes in MR signal intensity and contrast enhancement of lumbosacral vertebrae: do changes occur only inside the radiation therapy field? Radiology, 2002,222:179-183. [34] Choi CW,Chung JK,Lee DS,et al. Development of bone marrow immunoscintigraphy using a Tc-99m labeled anti-NCA-95 monoclonal antibody. Nucl Med Biol, 1995,22:117-123. [35] Cremerius U,Buell U. The present role of bone marrow scintigraphy. Eur J Nucl Med, 1999,26:191-193. [36] Liang Y,Bydder M,Yashar CM,et al. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys, 2012,In press. [37] Zhang FL,Cao JM,Xu WD. Bone marrow-sparing intensity-modulated radiotherapy for postoperative treatment of cervical cancer. Chinese-German J Clin Oncl, 2011,10:349-353. [38] Song WY,Huh SN,Liang Y,et al. Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer. J Appl Clin Med Phys, 2010,11:∶3255. [39] Menda Y,Ponto LL,Dornfeld KJ,et al. Investigation of the pharmacokinetics of 3′-deoxy-3′-[18F] fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol, 2010,37:433-438. [40] Hong L,Alektiar K,Chui C,et al. IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys, 2002,54:278-289. [41] Ahmed RS,Kim RY,Duan J,et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys, 2004,60:505-512. [42] Rose BS,Aydogan B,Liang Y,et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2011,79:800-807. [43] Albuquerque K,Giangreco D,Morrison C,et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys, 2011,79:1043-1047.
2013, Vol. 22 
